Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) is expected to issue its quarterly earnings data on Monday, March 24th. Analysts expect the company to announce earnings of ($1.23) per share for the quarter.
Phio Pharmaceuticals Stock Down 3.0 %
PHIO stock opened at $1.29 on Friday. The company’s 50-day simple moving average is $1.93 and its 200-day simple moving average is $2.46. Phio Pharmaceuticals has a 52-week low of $1.22 and a 52-week high of $9.79. The firm has a market cap of $8.89 million, a P/E ratio of -0.12 and a beta of 1.28.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Recommended Stories
- Five stocks we like better than Phio Pharmaceuticals
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
